Walgreens Boots Alliance (WBA)
(Delayed Data from NSDQ)
$8.71 USD
-0.27 (-3.01%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $8.73 +0.02 (0.23%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth D Momentum D VGM
Company Summary
Walgreens Boots Alliance, the world’s first pharmacy-led, health and well-being enterprise, has been formed through the combination of Walgreens Co. (WAG) and Alliance Boots. The merger brought together two leading companies with iconic brands, complementary geographic footprints, shared values, and trusted health care services through pharmaceutical wholesaling and community pharmacy care. The company includes the largest global pharmaceutical wholesaler and distribution network with over 390 distribution centers delivering to more than 230,000 pharmacies, doctors, health centers and hospitals every year across 20 countries. In addition, Walgreens Boots Alliance is the world's largest purchaser of prescription drugs ...
Company Summary
Walgreens Boots Alliance, the world’s first pharmacy-led, health and well-being enterprise, has been formed through the combination of Walgreens Co. (WAG) and Alliance Boots. The merger brought together two leading companies with iconic brands, complementary geographic footprints, shared values, and trusted health care services through pharmaceutical wholesaling and community pharmacy care. The company includes the largest global pharmaceutical wholesaler and distribution network with over 390 distribution centers delivering to more than 230,000 pharmacies, doctors, health centers and hospitals every year across 20 countries. In addition, Walgreens Boots Alliance is the world's largest purchaser of prescription drugs and several other health and wellbeing products. Its portfolio of retail and business brands includes Walgreens, Duane Reade, Boots and Alliance Healthcare, as well as global health and popular beauty product brands such as No7, Botanics, Liz Earle and Soap & Glory.
Segments in Detail
Historically, the legacy Walgreens used to report as one segment, which comprised the performance of Walgreens in the U.S.; its corporate costs and synergies from the Walgreens Boots Alliance Development joint venture, also known as WBAD; and equity earnings from Alliance Boots on a three-month lag. Following the combination of Alliance Boots and the legacy Walgreens, Walgreens Boots eliminated the three-month reporting lag and recast prior period results with no lag.
Following Walgreens Boots’ announcement regarding the sale of the majority of its Alliance Healthcare business and a portion of the Retail ;harmacy International segment's businesses in Europe to AmerisourceBergen, the company has reorganized its remaining businesses into two reportable operating segments — United States and International.
The company has three reportable segments — U.S. Retail Pharmacy (comprising 79.3% of total revenues in 2023), U.S. Healthcare (4.7% of total revenues in 2023 ) and International (15.9% of total revenues in 2023).
General Information
Walgreens Boots Alliance, Inc
108 Wilmot Road
Deerfield, IL 60015
Phone: 847-315-3700
Fax: 847-914-2804
Web: http://www.walgreensbootsalliance.com
Email: investor.relations@wba.com
Industry | Retail - Pharmacies and Drug Stores |
Sector | Retail-Wholesale |
Fiscal Year End | August |
Last Reported Quarter | 8/31/2024 |
Earnings Date | 10/15/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.36 |
Current Year EPS Consensus Estimate | 2.86 |
Estimated Long-Term EPS Growth Rate | 5.00 |
Earnings Date | 10/15/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 8.98 |
52 Week High | 27.05 |
52 Week Low | 8.46 |
Beta | 0.70 |
20 Day Moving Average | 20,300,636.00 |
Target Price Consensus | 11.73 |
4 Week | -10.47 |
12 Week | -26.33 |
YTD | -65.61 |
4 Week | -12.71 |
12 Week | -29.31 |
YTD | -71.29 |
Shares Outstanding (millions) | 863.28 |
Market Capitalization (millions) | 7,752.21 |
Short Ratio | NA |
Last Split Date | 2/16/1999 |
Dividend Yield | 11.14% |
Annual Dividend | $1.00 |
Payout Ratio | 0.32 |
Change in Payout Ratio | -0.06 |
Last Dividend Payout / Amount | 8/21/2024 / $0.25 |
Fundamental Ratios
P/E (F1) | 5.08 |
Trailing 12 Months | 2.84 |
PEG Ratio | 1.02 |
vs. Previous Year | -37.00% |
vs. Previous Quarter | -47.50% |
vs. Previous Year | 2.64% |
vs. Previous Quarter | -1.89% |
Price/Book | 0.51 |
Price/Cash Flow | 1.36 |
Price / Sales | 0.05 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 12.63 |
2/29/24 | 12.11 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 3.02 |
2/29/24 | 3.23 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 0.65 |
2/29/24 | 0.66 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 0.31 |
2/29/24 | 0.32 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 1.87 |
2/29/24 | 2.10 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -3.99 |
2/29/24 | -4.18 |
8/31/24 | Pending Next EPS Report |
5/31/24 | -9.34 |
2/29/24 | -9.84 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 17.67 |
2/29/24 | 17.61 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 13.64 |
2/29/24 | 13.68 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 0.49 |
2/29/24 | 0.50 |
8/31/24 | Pending Next EPS Report |
5/31/24 | 33.19 |
2/29/24 | 33.66 |